CG Oncology, Inc.
StreetZero Signal 57
About CG Oncology, Inc.
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Its lead drug candidate, CG0070, has reached Phase 3 testing as a monotherapy for non-muscle invasive bladder cancer. The company completed its IPO on NASDAQ under ticker CGON in January 2024 and has conducted subsequent public offerings of common stock.
LATEST FUNDINGRule 144
$186K
Announced 2026-10-15
TOTAL RAISED$556M
IN THE NEWS
- 🔗 CG Oncology Company Overview, Contact Details & Competitors | LeadIQ
- 🔗 CG Oncology - 2026 Company Profile, Team, Funding, Competitors & Financials - Tracxn
- 🔗 CG Oncology Announces Proposed Public Offering
- 🔗 CG Oncology IPO Timeline and Financing Details - Forge
- 🔗 CG Oncology Announces Pricing of Public Offering
EMPLOYEES—
FOUNDED—
HQIrvine, California, United States
Industry
Public Equity (NASDAQ)
Tags
BiopharmaceuticalOncologyPublicBladder Cancer
Key highlights
- Completed IPO on NASDAQ (CGON) in January 2024.
- Lead candidate CG0070 in Phase 3 for non-muscle invasive bladder cancer.
- Raised $120M Series E in 2023 led by ORI Capital, Longitude Capital and Decheng Capital.
- Conducted public offering of 9.2M shares of common stock in December 2024.
- Total funding exceeds $500M across rounds with focus on urologic cancers.
Ask StreetZero about CG Oncology, Inc.
Put our AI to work on this deal.
Similar companies
Other Public Equity (NASDAQ) deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account